Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2880070 With or Without Gemcitabine in Advanced or Metastatic Cancer (Part C Ovarian Focus)
2023-503459-91-00Phase 2Completed
- Sponsor
- Esperas Pharma Inc.
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of LY2880070 in cancer and High-Grade Serous Ovarian Cancer (HGSOC) (2 arms), sponsored by Esperas Pharma Inc. Primary endpoint: Safety and tolerability. Started Aug 2023; status: completed.
02
Drugs
LY2880070
03
Conditions
cancerHigh-Grade Serous Ovarian Cancer (HGSOC)
Beyond the preview
Go deeper on 2023-503459-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503459-91-00.